Payment overview · 2025
General Payments
$911.20
40 reported records · 13 companies
Healthcare provider profile · identity verified
Matthew David Mckee, DO
Allopathic & Osteopathic Physicians|Family Medicine|Sleep Medicine · ROOSEVELT, UT · NPI 1891149621
Verified facts
What the public records show
CMS Open Payments records show Matthew David Mckee, DO received $911.20 in general payments during 2025 across 40 reported records.
JAZZ PHARMACEUTICALS INC. accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $199.98 | 21.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $174.92 | 19.2% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $163.73 | 18.0% | 8 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $81.25 | 8.9% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $73.65 | 8.1% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $61.17 | 6.7% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $49.18 | 5.4% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $35.14 | 3.9% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $18.83 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.20 | 1.8% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $14.49 | 1.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.11 | 1.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $8.55 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $711.22 | 38 |
| Education | $199.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $199.98 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $131.76 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $115.11 | 8 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $81.25 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $73.65 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $61.17 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $49.18 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $47.69 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $46.72 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $35.14 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $12.12 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $8.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 77 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 14 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
65 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 333 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 322 | 89 |
| Atorvastatin Calcium | Atorvastatin Calcium | 268 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 76 |
| Lisinopril | Lisinopril | 229 | 66 |
| Losartan Potassium | Losartan Potassium | 214 | 59 |
| Gabapentin | Gabapentin | 192 | 49 |
| Furosemide | Furosemide | 191 | 61 |
| Trazodone Hcl | Trazodone Hcl | 171 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 47 |
| Ozempic | Semaglutide | 147 | 28 |
| Sertraline Hcl | Sertraline Hcl | 134 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 41 |
| Celecoxib | Celecoxib | 125 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 36 |
| Metformin Hcl | Metformin Hcl | 112 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 25 |
| Potassium Chloride | Potassium Chloride | 103 | 42 |
| Tramadol Hcl | Tramadol Hcl | 102 | 21 |
| Glipizide | Glipizide | 100 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 31 |
| Alprazolam | Alprazolam | 94 | 15 |
| Eliquis | Apixaban | 90 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 90 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 89 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 80 | 22 |
| Farxiga | Dapagliflozin Propanediol | 77 | 18 |
| Pregabalin | Pregabalin | 76 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 22 |
| Simvastatin | Simvastatin | 73 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 18 |
| Alendronate Sodium | Alendronate Sodium | 66 | 20 |
| Jardiance | Empagliflozin | 66 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 15 |
| Xarelto | Rivaroxaban | 65 | 15 |
| Metformin Hcl Er | Metformin Hcl | 60 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 60 | 19 |
| Allopurinol | Allopurinol | 56 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 17 |
| Ibuprofen | Ibuprofen | 56 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 52 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 12 |
| Montelukast Sodium | Montelukast Sodium | 51 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 14 |
| Meloxicam | Meloxicam | 47 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 47 | suppressed |
| Prednisone | Prednisone | 44 | 27 |
| Methocarbamol | Methocarbamol | 43 | 15 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Lorazepam | Lorazepam | 39 | 15 |
| Carvedilol | Carvedilol | 37 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 19 |
| Sucralfate | Sucralfate | 36 | 15 |
| Famotidine | Famotidine | 33 | suppressed |
| Finasteride | Finasteride | 33 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | 12 |
| Diazepam | Diazepam | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Naproxen | Naproxen | 25 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 21 |
| Estradiol | Estradiol | 23 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Butrans | Buprenorphine | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 11 |
| Telmisartan | Telmisartan | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $911.20 · 40 records | JAZZ PHARMACEUTICALS INC. | AIRSUPRA, BREZTRI, FARXIGA, GVOKE HYPOPEN, INSPIRE, JARDIANCE, Korlym, NEXPLANON, NURTEC ODT, Ohtuvayre, QULIPTA, Sunosi, TREMFYA, UBRELVY, VIBERZI, VRAYLAR, WatchPATONE, XYWAV, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error